Loxo Lays Out Plans For BTK Inhibitor LOXO-305 In CLL

Data At ASH Show Strong Post-Imbruvica Efficacy

 
• By Alaric DeArment
  
Leukemia cell (blast cell)
Loxo Oncology at Lilly announced Phase I/II data for its BTK inhibitor in CLL • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business